Novo Nordisk's Ozempic, Wegovy carve India's GLP-1 market amid patent cliff

• Novo Nordisk employs a dual-brand strategy in India for semaglutide, marketing Ozempic for Type 2 diabetes and Wegovy for chronic weight management.
• Ozempic focuses on glycemic control (up to 1mg weekly), while Wegovy targets significant weight reduction (up to 2.4mg weekly).
• The brands have distinct pricing, with Ozempic costing Rs.8,800-Rs.11,175 monthly and Wegovy ranging from Rs.10,850-Rs.16,400 after a price cut.
• This dual-brand approach enables market segmentation, ensures dosing clarity, and simplifies regulatory and insurance compliance.
• Semaglutide's patent expires in March 2026 in India, expected to lead to generic competition and significant price drops.

Why It Matters: Patent expiry will soon make key diabetes/obesity drugs cheaper and accessible in India.